Cambridge Epigenetics | GenomeWeb

Cambridge Epigenetics

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

The company was founded as a spinout of the University of Cambridge to commercialize an epigenetic sequencing technique called oxidative bisulfite sequencing.

Lab7 Systems has released a beta version of its next-generation sequencing data workflow management software platform, available for download to early-access users from the company's website. The company is planning updates to the software every four to six weeks.

This article was originally published May 17.
Startup firm Cambridge Epigenetix plans to commercialize an epigenetic sequencing technique, with the launch of its first product — called TrueMethyl — expected in August.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.